{‘She lacks little expertise’: the American healthcare community braces for Tracy Beth Høeg’s appointment at the FDA.
Given that the United States continues making sweeping changes to its immunization schedules, an unexpected name appears unexpectedly: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about coronavirus shots during the global health crisis and has zeroed in on alleged fatalities following Covid immunization in her brief position at the Food and Drug Administration.
Proposed Shifts to Childhood Vaccine Schedule
Health officials were set to unveil radical changes to the pediatric vaccination calendar recently, synchronizing the US with the Danish national calendar, according to reports – a major change that would put the US out of step with much of the world with no evidence for improved outcomes. The announcement has been postponed until the new year.
In place of the top vaccines chief, Dr. Høeg is set to present at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to lead the office this calendar year.
A New Direction at the Regulatory Body
This interim role might represent a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad solidify control at the agency – and it signals a increased emphasis upon reevaluating already-approved vaccines at the FDA.
Dr. Høeg has frequently advocated for halting certain pediatric shot schedules in the US in order to be more similar to Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.
In her initial comments, she has continued to focus on vaccination policy – usually the purview of Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.
Doubts Over Expertise
Høeg has no apparent experience in medication creation, oversight or leadership, which has been standard for past leaders of the CBER. She has worked at the FDA as a key advisor to the commissioner and CBER since earlier this year.
“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a major agency. She has no expertise in industry regulation.”
Previous heads of CBER would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that former directors who headed the center have had.”
CDER has an enormous workload at the FDA, she pointed out.
“Everybody just focuses on the innovative therapies, but the generic program authorizes numerous generic medications. There’s a biosimilars division, non-prescription drug unit and so forth, and each of these have to be managed,” Dr. Woodcock noted. “The area you neglect, that is precisely what that I always told people is going to bite you.”
Additionally, a major administrative component to the position, which supervises over 5,000 personnel. “It’s a massive management job, if you perform it correctly,” Woodcock concluded.
Response and Contentious Programs
When asked about inquiries about Høeg’s qualifications and whether this selection signifies greater collaboration among FDA leaders on vaccines, a press secretary said that the “inquiries stem from flawed presumptions”.
“Her resume is consistent with the functions of her role,” the representative said, pointing to the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.
As acting director, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial rapid therapy clearance system that allegedly concerned her former heads. “How are these therapies being chosen for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the FDA right now.”
Overall, he remarked, “the Food and Drug Administration looks to be trending towards laxer regulations of most medications, with the exception of vaccines.”
Established Past Work on Vaccines
Regarding vaccines, Høeg has a more established, if concerning, history, some experts observe. She authored a research paper using unverified volunteer-provided data to assess the rate of myocarditis following COVID-19 vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are riskier than they are.
Included in her “policy goals” for the incoming administration featured altering guidelines for recently developed shots and ending “non-essential” immunizations, she remarked following the vote on a audio program. At the agency, Dr. Høeg has according to sources floated the idea of barring teenage boys from obtaining COVID-19 vaccines.
“She is an all-around dogmatist who starts off with her beliefs and reverse-engineers to fit the science in a extremely disingenuous, untruthful way,” Dr. Howard said.
Gaining Influence and a “Revenge Tour”
Dr. Høeg aligned with fellow dissenters, {like|